UVI 3003
CAS: 847239-17-2
Ref. 3D-XIB23917
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Informação sobre produto
- 3-[4-Hydroxy-3-(5,5,8,8-Tetramethyl-3-Pentoxy-6,7-Dihydronaphthalen-2-Yl)Phenyl]Prop-2-Enoic Acid
UVI 3003 is a drug that is being developed for the treatment of cancer. It has been shown to activate the transcription factor, RAR-related orphan receptor alpha (RARα), which regulates the expression of basic proteins, fatty acids, and growth factors. UVI 3003 also activates Toll-like receptors (TLR) and increases the expression of TLR4 and TLR9. These receptors are responsible for initiating an immune response against bacteria in cells. The activation of TLR leads to a downregulation of these receptors, which leads to a reduction in inflammation caused by infection with bacteria. UVI 3003 has been shown to reposition drugs that have already been approved for other indications because it has the ability to inhibit cancer cell proliferation in vitro.
Propriedades químicas
Consulta técnica sobre: 3D-XIB23917 UVI 3003
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
